When to Give Digoxin
Digoxin should be given to patients with symptomatic heart failure (HF) with reduced ejection fraction (LVEF <40%) who remain symptomatic despite guideline-directed medical therapy (GDMT), or to patients with atrial fibrillation (AF) and HF with LVEF <40% for ventricular rate control. 1, 2
Primary Indications
Heart Failure with Reduced Ejection Fraction (HFrEF)
For patients in sinus rhythm:
- LVEF <40%
- NYHA functional class II-IV symptoms
- Already on optimal doses of ACEI/ARB, beta-blocker, and aldosterone antagonist (if indicated)
- Class of recommendation IIa, Level of Evidence B 1, 2
The goal here is to reduce hospitalizations for worsening HF—digoxin does not reduce mortality 1, 3, 4. The DIG trial demonstrated a 28% relative risk reduction in HF hospitalizations, though quality of life improvements were not consistently demonstrated 1.
For patients with atrial fibrillation:
- Ventricular rate at rest >80 bpm or at exercise >110-120 bpm
- LVEF <40%
- Use digoxin for rate control in addition to, or prior to, a beta-blocker
- Class of recommendation I, Level of Evidence C 1, 2
Digoxin is particularly useful for initial rate control in rapid AF and may be considered in decompensated HF patients before initiating a beta-blocker 1. However, recognize that beta-blockers (alone or combined with digoxin) are preferred long-term for rate control and mortality benefits 1, 2.
Critical Pre-Administration Criteria
Laboratory Requirements (MANDATORY)
Before giving digoxin, you must check:
- Serum potassium - Hypokalemia sensitizes the myocardium to digoxin toxicity even at therapeutic levels 1, 5
- Serum magnesium - Hypomagnesemia similarly increases toxicity risk 1, 5
- Renal function (serum creatinine/creatinine clearance) - Digoxin is primarily renally excreted; impaired function dramatically increases toxicity risk 5
- Serum calcium - Hypercalcemia predisposes to toxicity; hypocalcemia can nullify digoxin's effects 5
Absolute Contraindications
Do NOT give digoxin if:
- Second- or third-degree heart block without a permanent pacemaker 1, 2
- Pre-excitation syndromes (e.g., Wolff-Parkinson-White) 1, 2
- Previous documented digoxin intolerance 1, 2
- Ventricular tachycardia or ventricular fibrillation 5
Use with Extreme Caution
- Suspected sick sinus syndrome - may worsen conduction abnormalities 1, 2
- Acute myocardial infarction - increased myocardial oxygen demand may worsen ischemia 5
- Elderly patients (>70 years) - reduced renal clearance and increased half-life (69.6 vs 36.8 hours) 5, 6
- Thyroid disorders - hypothyroidism reduces digoxin requirements; hyperthyroidism increases resistance 5
Dosing Strategy
Maintenance Dosing (Preferred for Stable Patients)
Standard approach for chronic HF:
- Start with 0.25 mg once daily for patients <70 years with normal renal function 1, 5
- Use 0.125 mg once daily for patients >70 years, impaired renal function, or low lean body mass 1, 3, 5
- Use 0.0625 mg once daily (or every other day) for marked renal impairment 1, 5
Loading doses are generally NOT required in stable patients with sinus rhythm 1, 2. Steady-state concentrations are achieved in approximately 5 half-lives (1-3 weeks depending on renal function) 5.
Loading Dose (Only for Rapid Digitalization)
If rapid digitalization is medically necessary:
- Target peak body stores of 8-12 mcg/kg for normal renal function
- Use 6-10 mcg/kg for renal insufficiency 5
- Administer in divided doses: give approximately half initially, then additional fractions at 6-8 hour intervals 5
- Recent evidence suggests doses ≤12 mcg/kg ideal body weight are safer, with lower rates of toxic concentrations (≥1.2 ng/mL) 7
Critical caveat: Loading doses >12 mcg/kg IBW resulted in 50.6% of patients achieving SDC ≥1.2 ng/mL versus 30% with ≤12 mcg/kg, with no difference in rate control efficacy 7.
Therapeutic Monitoring
Target Serum Digoxin Concentration
- Optimal range: 0.6-1.2 ng/mL (lower than historically recommended) 1
- Concentrations >1.2 ng/mL are associated with increased mortality 3, 4, 8
- Sample timing: Draw levels just before the next dose or at least 6-8 hours after the last dose 1, 5
Ongoing Monitoring Requirements
- Serial electrolytes (potassium, magnesium) - mandatory due to arrhythmia risk with depletion 1, 5
- Renal function - periodically assess creatinine clearance 5
- Routine digoxin levels are not necessary unless toxicity is suspected or clinical response is inadequate 1, 5
Drug Interactions Requiring Dose Adjustment
These medications INCREASE digoxin levels:
- Amiodarone, quinidine, verapamil, diltiazem 1, 5
- Macrolide antibiotics (erythromycin, clarithromycin) 1, 5
- Itraconazole, propafenone, spironolactone 1, 5
If adding these agents, reduce digoxin dose by 50% and recheck levels in 1-2 weeks.
Common Pitfalls to Avoid
- Don't use digoxin as primary treatment for acute decompensated HF - it's for chronic outpatient management 9
- Don't rely on digoxin alone for rate control in AF during exercise - it works via vagotonic effects and fails during high sympathetic states 6
- Don't ignore renal function - patients with CrCl <60 mL/min are 2.6 times more likely to develop toxic levels with standard loading doses 10
- Don't use high doses (>0.25 mg daily) for rate control in AF - add beta-blockers or amiodarone instead 9
- Don't forget to check potassium before AND during therapy - hypokalemia from diuretics is a major contributor to toxicity 1, 5
Signs of Digoxin Toxicity
Watch for:
- Cardiac: AV block, atrial and ventricular arrhythmias (especially with hypokalemia) 1, 5
- Neurologic: Confusion, visual disturbances (yellow-green halos) 1, 5
- Gastrointestinal: Nausea, anorexia 1, 5
If toxicity occurs, consider digoxin-specific Fab antibody fragments for life-threatening ventricular arrhythmias 1, 11.